Evidence map›Paper›PMID 39389907›Full record

ReviewTrends in cancer2024

Engineering growth factor ligands and receptors for therapeutic innovation.

Xinran An, Justin Paoloni, Yuseong Oh, Jamie B Spangler

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xinran AnDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Justin PaoloniDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yuseong OhDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jamie B SpanglerDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: jamie.spangler@jhu.edu.

Funding

Divergent Roles for Hypoxia-Inducible Factor-1 and -2 in Ischemic Retinal DiseaseR01EY029750 · NEI · JOHNS HOPKINS UNIVERSITY · PI SODHI, AKRIT SINGH · 2019 to 2023
$2.6M
Molecular Engineering of Novel Therapies to Treat Corneal NeovascularizationR21EY033934 · NEI · JOHNS HOPKINS UNIVERSITY · PI SODHI, AKRIT SINGH · 2023 to 2024
$450k
NEI NIH HHS R01 EY029750NEI NIH HHS R21 EY033934
6 · The paper itself

Abstract

Growth factors signal through engagement and activation of their respective cell surface receptors to choreograph an array of cellular functions, including proliferation, growth, repair, migration, differentiation, and survival. Because of their vital role in determining cell fate and maintaining homeostasis, dysregulation of growth factor pathways leads to the development and/or progression of disease, particularly in the context of cancer. Exciting advances in protein engineering technologies have enabled innovative strategies to redesign naturally occurring growth factor ligands and receptors as targeted therapeutics. We review growth factor protein engineering efforts, including affinity modulation, molecular fusion, the design of decoy receptors, dual specificity constructs, and vaccines. Collectively, these approaches are catapulting next-generation drugs to treat cancer and a host of other conditions.

Indexed as

NeoplasmsProtein EngineeringAnimalsHumansIntercellular Signaling Peptides and ProteinsLigandsMolecular Targeted TherapyReceptors, Growth FactorRecombinant Fusion ProteinsSignal TransductionIntercellular Signaling Peptides and ProteinsLigandsReceptors, Growth FactorRecombinant Fusion Proteinscancer therapeuticsgrowth factorsligandmolecular designprotein engineeringreceptor

Identifiers

PMID39389907
PMCPMC11631651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.